Omeros Corporation’s Q4 2024 Earnings Call: Insights and Impacts
On March 31, 2025, at 4:30 PM ET, Omeros Corporation (NASDAQ: OMER) held its Q4 2024 earnings conference call. The call was hosted by Jennifer Williams from Cook Williams Communications, Inc., with key executives in attendance, including Gregory Demopulos, Chairman & CEO; David Borges, Chief Accounting Officer; Catherine Melfi, Chief Regulatory Officer; Nadia Dac, Chief Commercial Officer; and Steven Whitaker, VP, Clinical Development. This post provides a summary of the call, its potential impacts on shareholders, and the broader implications for the world.
Company Participants
- Jennifer Williams: Investor and Media relations, Cook Williams Communications, Inc.
- Gregory Demopulos: Chairman & CEO
- David Borges: Chief Accounting Officer
- Catherine Melfi: Chief Regulatory Officer
- Nadia Dac: Chief Commercial Officer
- Steven Whitaker: VP, Clinical Development
Conference Call Participants
- Steve Brozak: WBB
- Olivia Brayer: Cantor Fitzgerald
- John Gionco: Needham & Company
- Brandon Folkes: Rodman & Renshaw
The call began with Jennifer Williams welcoming participants and reminding everyone of the listen-only mode. She then introduced the Omeros executives, who each provided updates on their respective departments.
CEO’s Remarks
Gregory Demopulos started by highlighting the company’s progress in developing its MASP-3 technology, which is designed to target and neutralize specific proteins implicated in various diseases. He mentioned the successful completion of a Phase 3 trial for OMS701 in treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (TMA). Demopulos also discussed the progress of OMS906 in treating pain and inflammation, with Phase 2 data expected in 2026.
Financial Performance
David Borges discussed the financial highlights of the quarter, reporting a net loss of $22.7 million, or $0.17 per share. Revenue for the period was $4.6 million, primarily from the sale of OMS103HP for the prevention of primary immunoglobulin (IgG) replacement therapy in patients with primary immunodeficiency.
Regulatory Updates
Catherine Melfi provided updates on regulatory matters, including the ongoing discussions with the FDA regarding the potential approval of OMS701 for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. She also discussed the company’s plans to file an Investigational New Drug application for OMS906 in 2026.
Commercial Progress
Nadia Dac discussed commercial progress, reporting that OMS103HP sales for the quarter were $1.2 million, a 23% increase from the previous quarter. She also highlighted the launch of OMS701 in Europe and the potential for future growth in the market.
Clinical Development
Steven Whitaker discussed clinical development, focusing on the successful completion of the Phase 3 trial for OMS701 in TMA and the upcoming Phase 2 data for OMS906. He also mentioned the potential for future indications for the MASP-3 technology.
Impacts on Shareholders
The earnings call provided valuable insights into Omeros’ progress, with the successful completion of the Phase 3 trial for OMS701 and the potential approval in the US and Europe being particularly noteworthy. The ongoing discussions with the FDA and the potential for future indications for the MASP-3 technology also bode well for the company’s future growth. These updates, along with the commercial progress reported, were likely to be positively received by shareholders.
Impacts on the World
Beyond the impact on shareholders, the developments discussed during the call could have broader implications for the world. The potential approval of OMS701 for the treatment of TMA could provide a new therapeutic option for patients, reducing the burden of this often-deadly complication. The ongoing research into MASP-3 technology also holds the potential for the development of new treatments for various diseases, making a significant impact on global health.
Conclusion
In conclusion, Omeros Corporation’s Q4 2024 earnings call provided valuable updates on the company’s progress, with the successful completion of the Phase 3 trial for OMS701 and the potential approval in the US and Europe being particularly noteworthy. The ongoing discussions with the FDA and the potential for future indications for the MASP-3 technology also bode well for the company’s future growth. These updates, along with the commercial progress reported, were likely to be positively received by shareholders. Beyond the impact on shareholders, the developments discussed during the call could have broader implications for the world, providing new therapeutic options for patients and potentially leading to the development of new treatments for various diseases.
